Vismodegib (CAS: 879085-55-9) is an oral medication used in the treatment of advanced basal cell carcinoma (BCC), a type of skin cancer. It belongs to the class of hedgehog pathway inhibitors and has been shown to be effective in reducing tumor size and preventing disease progression.
Chemical Name:
2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methanesulfonylbenzamide
Molecular Formula:
C19H14Cl2N2O3S
Formula Weight:
421.3 g/mol
CAS No:
879085-55-9
Top Ten Keywords from Google and Synonyms:
Synonyms:
Health Benefits of this Product:
Vismodegib is primarily used in the treatment of advanced BCC, a type of skin cancer that can be difficult to treat with traditional therapies. Its targeted mechanism of action makes it a valuable option for patients who have not responded to other treatments or who are not candidates for surgery.
Potential Effects:
Vismodegib works by inhibiting smoothened, a key component of the hedgehog signaling pathway involved in tumor growth and progression. Its ability to target this pathway makes it a valuable tool for managing advanced BCC and reducing the risk of disease progression.
Product Mechanism:
Vismodegib works by inhibiting smoothened, a key component of the hedgehog signaling pathway involved in tumor growth and progression.
Safety:
As with all medications, proper precautions should be taken to ensure safe administration, and patients should be monitored closely for any potential side effects or adverse reactions.
Side Effects:
Common side effects of vismodegib include muscle spasms, loss of taste, hair loss, and weight loss. Rare but serious side effects may include cardiac events, renal failure, or secondary malignancies. Patients should be monitored regularly for potential side effects and seek medical attention if symptoms occur.
Dosing Information:
The recommended dose of vismodegib varies depending on the patient's individual needs and medical history. Consult a healthcare professional for specific dosing information.
Conclusion:
Vismodegib is a valuable tool in the management of advanced BCC, offering targeted therapy that has been proven effective in reducing tumor size and preventing disease progression. While proper precautions should be taken to ensure safe administration, the proven efficacy and safety profile of vismodegib make it a valuable development in the field of skin cancer treatment. Its unique mode of action targeting the hedgehog pathway also offers potential for the treatment of other types of cancers in the future
